Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Skin Testing Reagents for Penicillin Allergy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01818336
Recruitment Status : Completed
First Posted : March 26, 2013
Results First Posted : January 4, 2017
Last Update Posted : January 4, 2017
Sponsor:
Information provided by (Responsible Party):
AllerQuest LLC

Brief Summary:

A self- or parent-reported history of penicillin allergy excludes approximately 10% of the US population from receiving penicillin (Kerr 1994, Kagy, Blaiss 1998, Solensky et al. 2000, Neugut et al. 2001). Yet approximately 80% of patients labeled as allergic to the penicillins can safely take these antibiotics without fear of a life-threatening reaction (Gadde et al. 1993, Macy et al. 1997). The outcomes of this erroneous classification of patients include unnecessary denial of an effective and well-tolerated class of antibiotics, which are often the treatment of choice.

The primary aim of skin testing with the Penicillin Skin Test Kit is to identify subjects at very low risk of developing acute IgE-dependent reactions when given a penicillin or cross-reacting drug. The negative predictive value (NPV) of skin testing is assessed by oral challenge with a penicillin.


Condition or disease Intervention/treatment Phase
History of IgE Dependent Reaction to a Penicillin Product Drug: Penicillin skin test kit Phase 3

Detailed Description:

This is a prospective, open-label investigation of skin testing with the Penicillin Skin Test Kit in subjects at least 18 years of age with a self-reported history of possible IgE-dependent penicillin hypersensitivity.

At screening on Day 1, subjects and their parents/legal guardians (if applicable) will sign the informed consent form/ pediatric assent form. Following consent/assent, demographic information and medical history will be obtained, including prior and current medication use. Subjects will also be asked if they have had a respiratory infection in the past 2 weeks or antibiotics within the past 4 weeks. A physical examination will be performed, along with measurements of vital signs and, in subjects >5 years of age with active asthma, peak expiratory flow rate (PEFR). A urine pregnancy test will be obtained for all female subjects of childbearing potential.

The skin test procedure will first involve puncture testing. Skin test reagents will include the Penicillin Skin Test Kit, histamine (positive control), and sodium chloride (negative control). Subjects who have negative skin puncture test results to any of the drug antigens contained within the Penicillin Skin Test Kit will then undergo intradermal testing in duplicate. Subjects who have a positive reaction to one or more puncture or intradermal tests contained within the Penicillin Skin Test Kit will be discharged from the study. However, subjects with any positive skin test to drug antigens in the Penicillin Skin Test Kit will be asked to return for retesting (puncture and intradermal) in 4 weeks.

Subjects who have negative puncture and intradermal test results will be given the oral amoxicillin challenge, which will be comprised of a single, full oral dose of amoxicillin. The purpose of the oral amoxicillin challenge is to confirm lack of allergy and confirm the NPV (Negative Predictive Value) of skin testing. Subjects will be monitored at the study site for 1 hour following oral amoxicillin challenge and then sent home. The study site will follow-up by telephone with all subjects (or their parents/legal guardians in the case of young children) ≥72 hours after administration of the oral amoxicillin challenge.

Adverse events (AEs) will be recorded from administration of the Penicillin Skin Test throughout the 3-day study period as spontaneously reported by subjects or observed by the site staff.

Two normal subjects (i.e., no history of penicillin allergy) will be skin tested at each site to provide data on skin test specificity.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 481 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Confirmatory Study to Examine Negative Predictive Value (NPV) and Safety of Skin Testing With PRE-PEN, a Minor Determinant MIxture (MDM) of Penicillin Antigens, and Amoxicillin Reagent Against an Oral Challenge With Amoxicillin
Study Start Date : December 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Allergy

Arm Intervention/treatment
Experimental: all subjects

Intervention: Penicillin skin test kit

Subjects with negative intradermal tests will be given single oral amoxicillin challenge dose and followed for 72 hours for IgE dependent reactions.

Drug: Penicillin skin test kit
Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
Other Names:
  • PRE-PEN (benzylpenicilloyl polylysine)
  • MDM (minor determinant mixture of penicillins)
  • benzylpenicillin
  • benzylpenicilloate
  • benzylpenilloate
  • amoxicillin




Primary Outcome Measures :
  1. Negative Predictive Value [ Time Frame: 72 hours ]
    The primary endpoint was the negative predictive value (NPV), which was estimated as p = percentage of n history-positive subjects with negative skin tests from the Penicillin Allergy Skin Test Kit (as confirmed with an overall negative result for the skin puncture/intradermal testing) who do not experience an IgE-dependent hypersensitivity reaction within 72 hours of the oral amoxicillin challenge.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject must have provided written, informed consent prior to performance of any procedures.
  2. Subject can be male or female and must be generally healthy and at least 18 years of age.
  3. Subject must have a reported history of possible IgE dependent reaction to a penicillin or its semi-synthetic derivatives, including one or more of the following: anaphylaxis, decreased blood pressure and/or diminished consciousness, upper or lower airway obstruction, angioedema, urticaria, and/or generalized pruritic rash.

Exclusion Criteria:

  1. Subject who has exhibited a systemic allergic reaction to previous skin-test administration of PRE-PEN, MDM, or individual penicillin metabolites (benzylpenicillin, benzylpenicilloate, or benzylpenilloate).
  2. Subject who is pregnant or lactating.
  3. Subject who has had a respiratory infection within the past 2 weeks or has taken antibiotics of any kind during the past 2 weeks (except for topical antibiotics for acne).
  4. Subject who has taken an oral H1-antihistamine within 72 hours prior to skin testing.
  5. Subject who has taken hydroxyzine or doxepin within 7 days prior to skin testing.
  6. Subject who has had a penicillin reaction, including semisynthetic penicillins, within the last 6 weeks prior to skin testing.
  7. Subject who has received an investigational drug within 30 days prior to skin testing or who plans to participate in a study in which an investigational drug will be administered within the 30 days following skin testing.
  8. Subjects who have planned hospitalizations or medical or surgical procedures during the 72 hours following the oral amoxicillin challenge.
  9. Subjects who plan to take any new prescription or over-the-counter medications or herbal supplements during the 72 hours following the oral amoxicillin challenge.
  10. Subject who has had a previous adverse reaction to penicillin or semisynthetic derivative and subsequently tolerated a penicillin or semisynthetic derivative without an adverse experience.
  11. Subject who, in the investigator's opinion, has any other social or medical condition (e.g. fever, rash) that may place the subject at increased risk or may confound the interpretation of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01818336


Locations
Layout table for location information
United States, Alabama
Alabama Allergy & Asthma Center
Homewood, Alabama, United States, 35209
United States, Arizona
Allergy Associates of Tucson
Tucson, Arizona, United States, 85716
United States, California
Allergy & Asthma Clinical Research
Walnut Creek, California, United States, 94590
United States, Connecticut
Fairfield County Allergy, Asthma & Immunology Assoc., Inc.
Norwalk, Connecticut, United States, 06851
Ct. Asthma & Allergy Center LLC
West Hartford, Connecticut, United States, 06119
United States, Florida
Windom Allergy
Sarasota, Florida, United States, 34233
United States, Georgia
Atlanta Allergy and Asthma Clinic
Atlanta, Georgia, United States, 30060
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University Medical School
St. Louis, Missouri, United States, 63110
United States, Nebraska
Midwest Allergy & Asthma Clinic PC
Omaha, Nebraska, United States, 68130
United States, Oregon
Corvallis Clinic
Corvallis, Oregon, United States, 97330
United States, Tennessee
Allergy & Asthma Care
Germantown, Tennessee, United States, 38138
United States, Washington
Northwest Asthma & Allergy Center
Redmond, Washington, United States, 98052
Sponsors and Collaborators
AllerQuest LLC
Investigators
Layout table for investigator information
Study Director: N. Franklin Adkinson, Jr., MD AllerQuest LLC

Layout table for additonal information
Responsible Party: AllerQuest LLC
ClinicalTrials.gov Identifier: NCT01818336     History of Changes
Other Study ID Numbers: AQ-2010-001
AllerQuest LLC ( Other Grant/Funding Number: AQ-2010-001 )
First Posted: March 26, 2013    Key Record Dates
Results First Posted: January 4, 2017
Last Update Posted: January 4, 2017
Last Verified: November 2016
Keywords provided by AllerQuest LLC:
penicillin allergy
Additional relevant MeSH terms:
Layout table for MeSH terms
Amoxicillin
Penicillins
Anti-Bacterial Agents
Anti-Infective Agents